- Home
- TGTX vs POR Comparison
TGTX vs POR Comparison
Compare TGTX & POR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- POR
- Stock Information
- Founded
- TGTX 1993
- POR 1889
- Country
- TGTX United States
- POR United States
- Employees
- TGTX N/A
- POR N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- POR Electric Utilities: Central
- Sector
- TGTX Health Care
- POR Utilities
- Exchange
- TGTX Nasdaq
- POR Nasdaq
- Market Cap
- TGTX 5.5B
- POR 4.7B
- IPO Year
- TGTX 1995
- POR N/A
- Fundamental
- Price
- TGTX $32.18
- POR $47.68
- Analyst Decision
- TGTX Strong Buy
- POR Hold
- Analyst Count
- TGTX 5
- POR 12
- Target Price
- TGTX $48.20
- POR $46.91
- AVG Volume (30 Days)
- TGTX 1.8M
- POR 1.2M
- Earning Date
- TGTX 11-03-2025
- POR 10-31-2025
- Dividend Yield
- TGTX N/A
- POR 4.40%
- EPS Growth
- TGTX N/A
- POR N/A
- EPS
- TGTX 2.78
- POR 2.78
- Revenue
- TGTX $531,898,000.00
- POR $3,511,000,000.00
- Revenue This Year
- TGTX $82.31
- POR $5.06
- Revenue Next Year
- TGTX $49.05
- POR $4.84
- P/E Ratio
- TGTX $11.61
- POR $17.21
- Revenue Growth
- TGTX 100.88
- POR 5.09
- 52 Week Low
- TGTX $25.28
- POR $39.55
- 52 Week High
- TGTX $46.48
- POR $48.40
- Technical
- Relative Strength Index (RSI)
- TGTX 39.20
- POR 75.37
- Support Level
- TGTX $31.07
- POR $44.55
- Resistance Level
- TGTX $34.74
- POR $46.62
- Average True Range (ATR)
- TGTX 1.70
- POR 0.80
- MACD
- TGTX -0.27
- POR 0.16
- Stochastic Oscillator
- TGTX 17.74
- POR 85.99
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 100 megawatts of energy storage.